Forensics gone wrong: When DNA snares the innocent
By Douglas Starr,
Science/AAAS
| 03. 07. 2016
On a Tuesday morning in Boise, biologist Greg Hampikian is on speakerphone with Christopher Tapp, an inmate at the Idaho State Correctional Institution. Tapp is in prison for a murder he swears he did not commit. Many others think he’s innocent as well—lawyers, journalists, an organization of former judges; even the victim’s mother. No one has fought for him longer than Hampikian, a researcher at Boise State University (BSU). “How’re you doing, Chris?” Hampikian begins. “I’m having a good time at summer camp,” Tapp says gamely. “Although you know me … I’m in the hole again”—solitary. “There was a mutual misunderstanding between me and someone else.” He mentions that he and his wife are getting divorced.
“I’m really sorry Chris, that’s a lot to deal with,” Hampikian says. “You know my offer still stands. I’ll pay tuition for any courses you want to take.” A pause. “You know we got a decision from the court to move forward with a new DNA test. But the court is only allowing us a limited amount and we have to decide which test is...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...